|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
0801 / #1338 Skip Metastases in Children With Bone Tumors. Experience of the East European Sarcoma Groupтезисы доклада
- Авторы: Nisichenko D., Romantsova O., Khestanov D., Nisichenko O., Kharbedia V., Dzampaev A., Aliev M.
- Сборник: Pediatric Blood & Cancer SIOP Abstract
- Том: 69
- Тезисы
- Год издания: 2020
- Место издания: Wiley
- DOI: 10.1002/pbc.28742
- Аннотация: Background and Aims: Our monocenter study is aimed at studying the category of patients with skip-metastases, survival analysis, identifying factors that affect treatment and prognosis.Methods: Our study included 704 patients with osteosarcoma or Ewing sarcoma who received treatment from 01/2009 to 12/2019. An average age was 11.36 years. We analyzed groups with skip-metastases - 3.8% (27/704) and without. Boys - 59% (16/27), girls - 41% (11/27). In 13 children (48%), synchronous lung metastases were detected - stage IVa. In 5 children (18.5%), skip-metastases were identified retrospectively.Twenty-one patients (77.8%) underwent radical surgical treatment. In 6 patients (28.5%) - I grade of histological response (HR) (Huvos 1998) of the primary lesion, of which 1 patient - IV grade in skip metastasis. In 7 children (33.3%) - II grade HR, of which 1 patient - IV grade HR in skip-metastasis. In 8 patients (38%), the III and IV grades HR were revealed both in the bone tumor and in skip-metastasis.Results: 5/27 (18.5%) patients are alive with no evidence of disease (stage IVa - 2 patients); 9/27 (33.3%) are alive with signs of the disease; 13/27 (48%) – died of disease. The average follow-up was 21.7 months. The overall survival of 27 patients: 3-year -34%, 5-year- 22.7%. With osteosarcoma, overall survival: 3- and 5-year 28.7%. With Ewing sarcoma: 3-year - 50%, 5-year - 25%. No significant differences were obtained in the overall survival of patients with skip-metastases, depending on the location of metastasis. When comparing overall survival between the group with and without skip-metastasis, no significant difference was obtained p = 0.26.Conclusions: Aggressive multimodal therapy allows for satisfactory long-term survival, especially in patients in whom these metastases occur in the same bone as the primary lesion. Due to the rarity of identifying skip metastases, the analysis of this problem requires multicenter collaboration.
- Добавил в систему: Романцова Ольга Михайловна